Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

Steven Le Gouill; Monika Długosz-Danecka; Simon Rule; Pier Luigi Zinzani; Andre Goy; Stephen D. Smith; Jeanette K. Doorduijn; Carlos Panizo; Bijal D. Shah; Andrew J. Davies; Richard Eek; Eric Jacobsen; Arnon P. Kater; Tadeusz Robak; Preetesh Jain; Roser Calvo; Lin Tao; Michael Wang

doi:10.3324/haematol.2022.282469

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, Pier Luigi Zinzani, Andre Goy, Stephen D. Smith, Jeanette K. Doorduijn, Carlos Panizo, Bijal D. Shah, Andrew J. Davies, Richard Eek, Eric Jacobsen, Arnon P. Kater, Tadeusz Robak, Preetesh Jain, Roser Calvo, Lin Tao, Michael Wang^*

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

4 Citations (Scopus)

49 Downloads (Pure)

Original language	English
Pages (from-to)	343-350
Number of pages	8
Journal	Haematologica
Volume	109
Issue number	1
DOIs	https://doi.org/10.3324/haematol.2022.282469
Publication status	Published - Jan 2024

Access to Document

10.3324/haematol.2022.282469Licence: CC BY-NC

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed refractory mantle cell lymphoma, including those with poor prognostic factorsFinal published version, 3.87 MBLicence: CC BY-NC

Cite this

Le Gouill, S., Długosz-Danecka, M., Rule, S., Zinzani, P. L., Goy, A., Smith, S. D., Doorduijn, J. K., Panizo, C., Shah, B. D., Davies, A. J., Eek, R., Jacobsen, E., Kater, A. P., Robak, T., Jain, P., Calvo, R., Tao, L., & Wang, M. (2024). Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica, 109(1), 343-350. https://doi.org/10.3324/haematol.2022.282469

@article{4e5b38ee508e44eabafe61f092aff500,

title = "Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors",

author = "{Le Gouill}, Steven and Monika D{\l}ugosz-Danecka and Simon Rule and Zinzani, {Pier Luigi} and Andre Goy and Smith, {Stephen D.} and Doorduijn, {Jeanette K.} and Carlos Panizo and Shah, {Bijal D.} and Davies, {Andrew J.} and Richard Eek and Eric Jacobsen and Kater, {Arnon P.} and Tadeusz Robak and Preetesh Jain and Roser Calvo and Lin Tao and Michael Wang",

year = "2024",

month = jan,

doi = "10.3324/haematol.2022.282469",

language = "English",

volume = "109",

pages = "343--350",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "1",

}

Le Gouill, S, Długosz-Danecka, M, Rule, S, Zinzani, PL, Goy, A, Smith, SD, Doorduijn, JK, Panizo, C, Shah, BD, Davies, AJ, Eek, R, Jacobsen, E, Kater, AP, Robak, T, Jain, P, Calvo, R, Tao, L & Wang, M 2024, 'Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors', Haematologica, vol. 109, no. 1, pp. 343-350. https://doi.org/10.3324/haematol.2022.282469

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. / Le Gouill, Steven; Długosz-Danecka, Monika; Rule, Simon et al.
In: Haematologica, Vol. 109, No. 1, 01.2024, p. 343-350.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

AU - Le Gouill, Steven

AU - Długosz-Danecka, Monika

AU - Rule, Simon

AU - Zinzani, Pier Luigi

AU - Goy, Andre

AU - Smith, Stephen D.

AU - Doorduijn, Jeanette K.

AU - Panizo, Carlos

AU - Shah, Bijal D.

AU - Davies, Andrew J.

AU - Eek, Richard

AU - Jacobsen, Eric

AU - Kater, Arnon P.

AU - Robak, Tadeusz

AU - Jain, Preetesh

AU - Calvo, Roser

AU - Tao, Lin

AU - Wang, Michael

PY - 2024/1

Y1 - 2024/1

UR - http://www.scopus.com/inward/record.url?scp=85181852702&partnerID=8YFLogxK

U2 - 10.3324/haematol.2022.282469

DO - 10.3324/haematol.2022.282469

M3 - Comment/Letter to the editor

C2 - 37470152

AN - SCOPUS:85181852702

SN - 0390-6078

VL - 109

SP - 343

EP - 350

JO - Haematologica

JF - Haematologica

IS - 1

ER -

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

Access to Document

Other files and links

Cite this